Abstract
Beta-cell replacement is the only physiologically relevant alternative to insulin injections in patients with type 1 diabetes (T1D). Pancreas and islet transplantation from deceased organ donors can provide a new beta-cell pool to produce insulin, help blood glucose management, and delay secondary diabetes complications. For children and adolescents with T1D, whole pancreas transplantation is not a viable option because of surgical complications, whereas islet transplantation, even if it is procedurally simpler, must still overcome the burden of immunosuppression to become a routine therapy for children in the future.
Keywords:
diabetes; islet transplantation; pancreas transplantation.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
MeSH terms
-
Age Factors
-
Animals
-
Diabetes Complications / prevention & control
-
Diabetes Mellitus, Type 1 / complications
-
Diabetes Mellitus, Type 1 / economics
-
Diabetes Mellitus, Type 1 / immunology
-
Diabetes Mellitus, Type 1 / surgery*
-
Health Care Costs
-
Humans
-
Hyperglycemia / prevention & control
-
Hypoglycemia / prevention & control
-
Immunosuppression Therapy / adverse effects*
-
Immunosuppression Therapy / economics
-
Islets of Langerhans Transplantation / adverse effects*
-
Islets of Langerhans Transplantation / economics
-
Islets of Langerhans Transplantation / immunology
-
Islets of Langerhans Transplantation / standards
-
Pancreas Transplantation / adverse effects
-
Practice Guidelines as Topic
-
Tissue Donors / supply & distribution
-
Transplantation, Autologous / adverse effects
-
Transplantation, Autologous / economics
-
Transplantation, Autologous / standards
-
Transplantation, Heterologous / adverse effects
-
Transplantation, Heterologous / economics
-
Transplantation, Heterologous / standards
-
Transplantation, Homologous / adverse effects
-
Transplantation, Homologous / economics
-
Transplantation, Homologous / standards
-
United States
-
United States Food and Drug Administration